폐동맥 고혈압(PAH) 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 유형별, 약물 유형별, 투여 경로별, 지역별, 부문별 예측(2023-2032년)

The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report "Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.

During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.

In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.

The global key market players include: Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Generics
• Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
• Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

• Intravenous/ subcutaneous
• Inhalational
• Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Pulmonary Arterial Hypertension Market Insights

• 4.1. Pulmonary Arterial Hypertension Market - Route of Administration Snapshot
• 4.2. Pulmonary Arterial Hypertension Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Cases of Pulmonary Arterial Hypertension (PAH) Facilitate Market Growth
    • 4.2.1.2. Advancement of soluble guanylate cyclase (SGC)-stimulating drugs
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Expiration of critical patents
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Pulmonary Arterial Hypertension Market Route of Administration Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Pulmonary Arterial Hypertension Market, by Drug Class

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
• 5.3. PDE-5 Inhibitors
  • 5.3.1. Global Pulmonary Arterial Hypertension Market, by PDE-5 Inhibitors, by Region, 2019-2032 (USD Billion)
• 5.4. Prostacyclin and Prostacyclin Analogs
  • 5.4.1. Global Pulmonary Arterial Hypertension Market, by Prostacyclin and Prostacyclin Analogs, by Region, 2019-2032 (USD Billion)
• 5.5. SGC Stimulators
  • 5.5.1. Global Pulmonary Arterial Hypertension Market, by SGC Stimulators, by Region, 2019-2032 (USD Billion)
• 5.6. Endothelin Receptor Antagonists (ERAs)
  • 5.6.1. Global Pulmonary Arterial Hypertension Market, by Endothelin Receptor Antagonists (ERAs), by Region, 2019-2032 (USD Billion)

6. Global Pulmonary Arterial Hypertension Market, by Type

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
• 6.3. Generics
  • 6.3.1. Global Pulmonary Arterial Hypertension Market, by Generics, by Region, 2019-2032 (USD Billion)
• 6.4. Branded
  • 6.4.1. Global Pulmonary Arterial Hypertension Market, by Branded, by Region, 2019-2032 (USD Billion)

7. Global Pulmonary Arterial Hypertension Market, by Route of Administration

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
• 7.3. Intravenous/ subcutaneous
  • 7.3.1. Global Pulmonary Arterial Hypertension Market, by Intravenous/ subcutaneous, By Region, 2019-2032 (USD Billion)
• 7.4. Inhalational
  • 7.4.1. Global Pulmonary Arterial Hypertension Market, by Inhalational, By Region, 2019-2032 (USD Billion)
• 7.5. Oral
  • 7.5.1. Global Pulmonary Arterial Hypertension Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Pulmonary Arterial Hypertension Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
• 8.3. Pulmonary Arterial Hypertension Market - North America
  • 8.3.1. North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 8.3.2. North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.3.3. North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.3.4. Pulmonary Arterial Hypertension Market - U.S.
    • 8.3.4.1. U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.4.2. U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.4.3. U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.3.5. Pulmonary Arterial Hypertension Market - Canada
    • 8.3.5.1. Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.5.2. Canada.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.5.3. Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
• 8.4. Pulmonary Arterial Hypertension Market - Europe
  • 8.4.1. Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 8.4.2. Europe.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.4.3. Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.4. Pulmonary Arterial Hypertension Market - UK
    • 8.4.4.1. UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.4.2. UK.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.4.3. UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.5. Pulmonary Arterial Hypertension Market - France
    • 8.4.5.1. France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.5.2. France.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.5.3. France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.6. Pulmonary Arterial Hypertension Market - Germany
    • 8.4.6.1. Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.6.2. Germany.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.6.3. Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.7. Pulmonary Arterial Hypertension Market - Italy
    • 8.4.7.1. Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.7.2. Italy.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.7.3. Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.8. Pulmonary Arterial Hypertension Market - Spain
    • 8.4.8.1. Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.8.2. Spain.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.8.3. Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.9. Pulmonary Arterial Hypertension Market - Netherlands
    • 8.4.9.1. Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.9.2. Netherlands.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.9.3. Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4.10. Pulmonary Arterial Hypertension Market - Russia
    • 8.4.10.1. Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.10.2. Russia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.10.3. Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
• 8.5. Pulmonary Arterial Hypertension Market - Asia Pacific
  • 8.5.1. Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 8.5.2. Asia Pacific.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.5.3. Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.4. Pulmonary Arterial Hypertension Market - China
    • 8.5.4.1. China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.4.2. China.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.4.3. China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.5. Pulmonary Arterial Hypertension Market - India
    • 8.5.5.1. India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.5.2. India.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.5.3. India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.6. Pulmonary Arterial Hypertension Market - Malaysia
    • 8.5.6.1. Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.6.2. Malaysia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.6.3. Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.7. Pulmonary Arterial Hypertension Market - Japan
    • 8.5.7.1. Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.7.2. Japan.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.7.3. Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.8. Pulmonary Arterial Hypertension Market - Indonesia
    • 8.5.8.1. Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.8.2. Indonesia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.8.3. Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5.9. Pulmonary Arterial Hypertension Market - South Korea
    • 8.5.9.1. South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.9.2. South Korea.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.9.3. South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
• 8.6. Pulmonary Arterial Hypertension Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 8.6.2. Middle East & Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.6.3. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6.4. Pulmonary Arterial Hypertension Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.4.2. Saudi Arabia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6.5. Pulmonary Arterial Hypertension Market - UAE
    • 8.6.5.1. UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.5.2. UAE.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.5.3. UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6.6. Pulmonary Arterial Hypertension Market - Israel
    • 8.6.6.1. Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.6.2. Israel.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.6.3. Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6.7. Pulmonary Arterial Hypertension Market - South Africa
    • 8.6.7.1. South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.7.2. South Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.7.3. South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
• 8.7. Pulmonary Arterial Hypertension Market - Latin America
  • 8.7.1. Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 8.7.2. Latin America.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.7.3. Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7.4. Pulmonary Arterial Hypertension Market - Mexico
    • 8.7.4.1. Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.4.2. Mexico.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.4.3. Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7.5. Pulmonary Arterial Hypertension Market - Brazil
    • 8.7.5.1. Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.5.2. Brazil.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.5.3. Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7.6. Pulmonary Arterial Hypertension Market - Argentina
    • 8.7.6.1. Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.6.2. Argentina.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.6.3. Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Bayer
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Gilead Sciences, Inc.
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. GlaxoSmithKline
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Johnson & Johnson
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Lupin Pharmaceuticals, Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Sandoz Inc. (Novartis)
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Sun Pharmaceutical Industries, Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Teva Pharmaceutical Industries Ltd.
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. United Therapeutics Corporation
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Viatris Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development